XML 24 R18.htm IDEA: XBRL DOCUMENT v3.24.3
Employee Benefits
9 Months Ended
Sep. 30, 2024
Retirement Benefits [Abstract]  
Employee Benefits

10. Employee Benefits

Share-Based Compensation

Share-based compensation expense is classified in the condensed consolidated statements of operations and comprehensive loss as follows:

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

 

 

(in thousands)

 

 

(in thousands)

 

Research and development

 

$

7,166

 

 

$

2,959

 

 

$

14,281

 

 

$

8,859

 

General and administrative

 

 

6,326

 

 

 

4,356

 

 

 

15,690

 

 

 

10,659

 

Total

 

$

13,492

 

 

$

7,315

 

 

$

29,971

 

 

$

19,518

 

 

The weighted-average grant date fair value of options, estimated as of the grant date using the Black Scholes option pricing model was $25.01 per option for the 2,954,935 options granted during the nine months ended September 30, 2024. The following assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2024.

 

Volatility

 

67.6

%

Risk-free interest rate

 

4.4

%

Expected holding period (in years)

 

6.2

 

Dividend yield

 

-

 

 

 

Contingent Share Option Awards

On February 1, 2024, the Board of Directors approved the grant of share options to purchase 2,446,045 common shares, at an exercise price of $36.09 per share, to employees as the annual grant for 2024. These share option grants were approved subject to Company's general meeting resolving upon, and the Board of Directors having implemented through an amendment to the Company's articles of association, an increase in the authorized share capital sufficient to satisfy the award set forth in the resolution (such shareholder resolution to be proposed to the Company's annual general meeting to be held in 2024) (the “Shareholder Approval Condition”), provided that such options will be forfeited if the Shareholder Approval Condition is not satisfied ultimately by January 1, 2025. On May 7, 2024, the shareholders approved the amendment to the Company’s articles of association, including the requisite increase in the authorized share capital satisfying the Shareholder Approval Condition, therefore the grant-date fair value of the contingent shares is based on the Black-Scholes valuation model based on the fair market value of the share on the shareholder approval date. Share-based compensation expense was recorded beginning in the second quarter of 2024 relating to these contingent share option awards.